Genomic medicine in non-small cell lung cancer: Paving the path to personalized care

Respirology

Volumn 16, Issue 2, 2011, Pages 257-263

  Sriram, Krishna Bajee ^a,b   Larsen, Jill Everland ^b,c   Yang, Ian Anthony ^a,b   Bowman, Rayleen Veronica ^a,b   Fong, Kwun Meng ^a,b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

genomics; microarray; non small cell lung cancer; personalized medicine

Indexed keywords

MICRORNA;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COPY NUMBER VARIATION; DNA METHYLATION; DNA SEQUENCE; GENE EXPRESSION; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 79551511484     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01892.x     Document Type: Review

References (69)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
3. Spiro SG, Silvestri GA,. One hundred years of Lung cancer. Am. J. Respir. Crit. Care Med. 2005; 172: 523-9.
4. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N. Engl. J. Med. 2008; 359: 1367-80.
5. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int. J. Cancer 2007; 120: 868-74.
6. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and Lung cancer outcomes. JAMA 2007; 297: 953-61.
7. Chansky K, Sculier J-P, Crowley JJ, et al. The International Association for the Study of Lung Cancer staging project prognostic factors and pathologic TNM stage in surgically managed non-small cell Lung cancer. J. Thorac. Oncol. 2009; 4: 792-801.
8. Detterbeck FC, Boffa DJ, Tanoue LT,. The new Lung cancer staging system. Chest 2009; 136: 260-71.
9. Hoffman PC, Mauer AM, Vokes EE,. Lung cancer. Lancet 2000; 355: 479-85.
10. Pisters KMW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J. Clin. Oncol. 2007; 25: 5506-18.
11. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell Lung cancer, stage IV. Chest 2007; 132 (Suppl. 3): 277S-89S.
12. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007; 7: 169-81.
13. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-24.
14. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-70.
15. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 2007; 13: 361-6.
16. Beane J, Sebastiani P, Whitfield TH, et al. A prediction model for Lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev. Res. 2008; 1: 56-64.
17. Boyle JO, GümüÅ ZH, Kacker A, et al. Effects of Cigarette Smoke on the Human Oral Mucosal Transcriptome. Cancer Prev. Res. 2010; 3: 266-78.
18. Sridhar S, Schembri F, Zeskind J, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008; 9: 259.
19. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. USA 2001; 98: 13784-9.
20. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001; 98: 13790-95.
21. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 2006; 24: 5079-90.
22. Larsen JE, Pavey SJ, Bowman R, et al. Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur. Respir. J. 2007; 30: 21-6.
23. Beer DG, Kardia SLR, Huang C-C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002; 8: 816-24.
24. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2007; 356: 11-20.
25. Guo L, Ma Y, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin. Cancer Res. 2006; 12: 3344-54.
26. Guo NL, Wan Y-W, Tosun K, et al. Confirmation of gene expression-based prediction of survival in non-small cell Lung cancer. Clin. Cancer Res. 2008; 14: 8213-20.
27. Larsen JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007; 28: 760-66.
28. Larsen JE, Pavey SJ, Passmore LH, et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin. Cancer Res. 2007; 13: 2946-54.
29. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage Non Small-Cell Lung Cancer. J. Clin. Oncol. 2007; 25: 5562-9.
30. Lu Y, Lemon W, Liu P-Y, et al. A gene expression signature predicts survival of patients with stage I non-small cell Lung cancer. PLoS Med. 2006; 3: e467.
31. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 2006; 355: 570-80.
32. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the Lung. Cancer Res. 2006; 66: 7466-72.
33. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-70.
34. Boutros PC, Lau SK, Pintille M, et al. Prognostic gene signatures for non-small cell lung cancer. Proc. Natl. Acad. Sci. USA 2009; 106: 2824-8.
35. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin. Cancer Res. 2008; 14: 5565-70.
36. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell Lung cancer. Clin. Cancer Res. 2009; 15: 284-90.
37. Shedden K, Taylor JMG, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 2008; 14: 822-7.
38. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the Lung. Clin. Cancer Res. 2008; 14: 4794-9.
39. Sun Z, Wigle DA, Yang P,. Non-overlapping and non-cell-type-specific gene expression signatures predict Lung cancer survival. J. Clin. Oncol. 2008; 26: 877-83.
40. Bianchi F,. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J. Clin. Invest. 2007; 117: 3436-44.
41. Reed CE, Graham A, Hoda RS, et al. A simple two-gene prognostic model for adenocarcinoma of the lung. J. Thorac. Cardiovasc. Surg. 2008; 135: 627-34.
42. Lee R, Feinbaum R, Ambros V,. A short history of a short RNA. Cell 2004; 116 (Suppl. 2): S89-92.
43. He L, Hannon GJ,. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004; 5: 522-31.
44. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
45. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. Cancer Res. 2004; 64: 3753-6.
46. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006; 6: 857-66.
47. Yu S-L, Chen H-Y, Chang G-C, et al. MicroRNA signature predicts survival and relapse in Lung cancer. Cancer Cell 2008; 13: 48-57.
48. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature MicroRNA-21 and MicroRNA-205 overexpression in non-small cell Lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008; 54: 1696-704.
49. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell Lung cancer. Cancer Res. 2009; 69: 5776-83.
50. Goeze A, Schlüns K, Wolf G, et al. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J. Pathol. 2002; 196: 8-16.
51. Petersen S, Aninat-Meyer M, Schluns K, et al. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br. J. Cancer 2000; 82: 65-73.
52. Boelens MC, Kok K, van der Vlies P, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer 2009; 66: 372-8.
53. Broet P, Camilleri-Broet S, Zhang S, et al. Prediction of clinical outcome in multiple Lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res. 2009; 69: 1055-62.
54. Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in non-small cell Lung cancer, identification of HSP90 as potential target. PLoS ONE 2008; 3: e0001722.
55. Rosell R, Felip E, Paz-Ares L,. How could pharmacogenomics help improve patient survival? Lung Cancer 2007; 57 (Suppl. 2): S35-41.
56. Györffy B, Surowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 2006; 118: 1699-712.
57. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol. 2007; 25: 4350-57.
58. Zhu C-Q, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell Lung cancer. J. Clin. Oncol. 2010; 28: 4417-24.
59. Perez-Soler R,. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 2009; 28 (Suppl. 1): S38-45.
60. Balko J, Potti A, Saunders C, et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 2006; 7: 289.
61. Choi K, Creighton CJ, Stivers D, et al. Transcriptional profiling of non-small cell Lung cancer cells with activating EGFR somatic mutations. PLoS ONE 2007; 2: e1226.
62. Tan E-H, Ramlau R, Pluzanska A, et al. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann. Oncol. 2010; 21: 217-22.
63. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004; 351: 2817-26.
64. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002; 347: 1999-2009.
65. Sparano JA, Paik S,. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 2008; 26: 721-8.
66. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 2008; 26: 729-35.
67. Subramanian J, Simon R,. Gene expression-based prognostic singatures in Lung cancer: ready for clinical use? J. Natl. Cancer Inst. 2010; 102: 464-74.
68. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 2006; 24: 1151-61.
69. Baty F, Facompre M, Kaiser S, et al. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell Lung cancer. Am. J. Respir. Crit. Care Med. 2010; 181: 181-8.